Effect of @entity10055 on Indirect XXXX in Neonates Treated With Phototherapy.

@entity1 @entity1087 @entity648 @entity3638 @entity10055
BACKGROUND: @entity3638 is a common neonatal problem. The present study aimed to investigate the effect of @entity10055 in reducing indirect @entity3638 of @entity1 under phototherapy. METHODS: This double-blind randomized clinical trial was conducted on neonates with @entity1087 , who had received phototherapy in the hospitals affiliated with the Shiraz University of Medical Sciences in 2013. A total of 80 neonates were enrolled in the study and were randomly divided into 2 groups. The intervention group (n = 0) with indirect @entity3638 received 10 mg    kg(-1)    day(-1) divided every 12 hours Ursobil (capsule 300 mg) in addition to phototherapy, whereas the control group (n = 0) received only phototherapy. Total @entity648 levels were measured every 12 hours until reaching <10 mg/dL, and then phototherapy was disrupted. The duration of phototherapy was measured. The 2 groups were compared regarding total @entity648 levels at different time points and duration of phototherapy using the generalized estimating equation (GEE) test. RESULTS: The mean of total @entity648 in the intervention group was 12    1.6, 10    1.1, and 9.8    0.2 mg/dL 12, 24, and 48 hours after the beginning of phototherapy, respectively. On the contrary, these measures were 14.4    1.3, 12.5    1.4, and 10.1    1.1 mg/dL in the control group, respectively, (P < 0.05). The mean time required for phototherapy to decrease the @entity648 level to < 10 mg/dL was 15.5    6 and 44.6    13.3 hours in the case and the control group, respectively, (P = 0.001). CONCLUSIONS: @entity10055 had additive effect with phototherapy in neonates with indirect @entity3638 . This drug also reduced the time period needed for phototherapy and, consequently, decreased the hospitalization period.
